Ultragenyx Pharmaceutical Inc. (LON:0LIF)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.96B -0.4% |
| Revenue (ttm) | 540.40M +17.5% |
| Net Income | -441.67M |
| EPS | -4.39 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,765 |
| Open | 26.62 |
| Previous Close | 26.76 |
| Day's Range | 26.47 - 27.70 |
| 52-Week Range | 18.00 - 41.50 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.18% compared to the previous year's $560.00 million. Losses were -$575.00 million, 1.05% more than in 2024.
Financial numbers in USD Financial StatementsNews
Ultragenyx price target raised to $81 from $79 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $81 from $79 and keeps a Buy rating on the shares. The firm said 2Q26 earnings report…
Ultragenyx price target lowered to $45 from $47 at Wells Fargo
Wells Fargo lowered the firm’s price target on Ultragenyx (RARE) to $45 from $47 and keeps an Overweight rating on the shares. The firm is constructive ahead of GTX-102 Phase…
Ultragenyx Pharmaceutical Earnings Call Transcript: Q2 2026
Record Q2 revenue of $214M was driven by strong global demand for key products and robust commercial execution. Two gene therapy BLAs are under FDA review with launches anticipated in late 2026, and profitability is targeted for 2027, supported by disciplined expense management and PRV monetization.
Ultragenyx Pharmaceutical Earnings release: Q2 2026
Ultragenyx Pharmaceutical released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Ultragenyx Pharmaceutical Quarterly report: Q2 2026
Ultragenyx Pharmaceutical has published its Q2 2026 quarterly earnings report on August 4, 2026.
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Second quarter total revenue of $214 million, Crysvita® revenue of $156 million and Dojolvi® revenue of $27 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 m...
Ultragenyx price target lowered to $35 from $43 at Guggenheim
Guggenheim lowered the firm’s price target on Ultragenyx (RARE) to $35 from $43 and keeps a Buy rating on the shares. Should the ASPIRE readout in Q3 be overwhelmingly positive,…
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
NOVATO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) agains...
Ultragenyx price target raised to $30 from $26 at Wedbush
Wedbush raised the firm’s price target on Ultragenyx (RARE) to $30 from $26 and keeps a Neutral rating on the shares. The firm updated its model ahead of the Q2…
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report, detailing the company's work on behalf of patients and families living ...
Ultragenyx price target raised to $40 from $35 at RBC Capital
RBC Capital raised the firm’s price target on Ultragenyx (RARE) to $40 from $35 and keeps an Outperform rating on the shares as part of a broader research note previewing…
Ultragenyx Pharmaceutical Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Key phase III Angelman data and two gene therapy launches are expected to drive a transformative year, with profitability targeted for 2027. Strong clinical results, robust manufacturing, and strategic PRV monetization support a solid financial outlook and pipeline expansion.
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...
Ultragenyx price target raised to $96 from $84 at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Ultragenyx (RARE) to $96 from $84 and keeps an Overweight rating on the shares. The investment case argues that…
Ultragenyx Pharmaceutical Transcript: AGM 2026
The meeting established a quorum, presented four key proposals, and saw all measures—including director elections, incentive plan approval, auditor ratification, and executive compensation—approved by shareholders. No questions were raised during the Q&A.
Ultragenyx Pharmaceutical Transcript: Bank of America Global Healthcare Conference 2026
Revenue guidance is reaffirmed for the year, with profitability targeted for 2027 through growth in current and new products. Key catalysts include upcoming phase III Angelman data and two gene therapy launches, both supported by strong clinical and commercial preparation.
Ultragenyx price target lowered to $33 from $34 at Evercore ISI
Evercore ISI lowered the firm’s price target on Ultragenyx (RARE) to $33 from $34 and keeps an Outperform rating on the shares.
Ultragenyx price target lowered to $26 from $27 at Wedbush
Wedbush lowered the firm’s price target on Ultragenyx (RARE) to $26 from $27 and keeps a Neutral rating on the shares. While the top-line miss is disappointing, the firm looks…
Ultragenyx price target lowered to $43 from $52 at Guggenheim
Guggenheim lowered the firm’s price target on Ultragenyx (RARE) to $43 from $52 and keeps a Buy rating on the shares. The firm lowered its target to reflect challenges with…
Rare disease families find roadmap to drug development at bootcamps.
Ultragenyx's Rare Bootcamp is a multi-day forum that helps families learn about conducting rare disease research and the steps that go into developing a new drug.
Rare disease families find roadmap to drug development at bootcamps
Rare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx's Rare Bootcamp gives advocates a roadmap for navigating drug development.
Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference
NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...
Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026
Q1 2026 revenue reached $136M, with strong growth in EVKEEZA and steady performance in CRYSVITA and DOJOLVI. 2026 revenue guidance is $730–$760M, with profitability targeted for 2027 and multiple new gene therapy launches anticipated.